Abstract
Background Robust biomarkers that predict disease outcomes amongst COVID-19 patients are necessary for both patient triage and resource prioritisation. Numerous candidate biomarkers have been proposed for COVID-19. However, at present, there is no consensus on the best diagnostic approach to predict outcomes in infected patients. Moreover, it is not clear whether such tools would apply to other potentially pandemic pathogens and therefore of use as stockpile for future pandemic preparedness.
Methods We conducted a multi-cohort observational study to investigate the biology and the prognostic role of interferon alpha-inducible protein 27 (IFI27) in COVID-19 patients.
Findings We show that IFI27 is expressed in the respiratory tract of COVID-19 patients and elevated IFI27 expression is associated with the presence of a high viral load. We further demonstrate that systemic host response, as measured by blood IFI27 expression, is associated with COVID-19 severity. For clinical outcome prediction (e.g. respiratory failure), IFI27 expression displays a high positive (0.83) and negative (0.95) predictive value, outperforming all other known predictors of COVID-19 severity. Furthermore, IFI27 is upregulated in the blood of infected patients in response to other respiratory viruses. For example, in the pandemic H1N1/09 swine influenza virus infection, IFI27-like genes were highly upregulated in the blood samples of severely infected patients.
Interpretation These data suggest that prognostic biomarkers targeting the family of IFI27 genes could potentially supplement conventional diagnostic tools in future virus pandemics, independent of whether such pandemics are caused by a coronavirus, an influenza virus or another as yet-to-be discovered respiratory virus.
Evidence before this study We searched the scientific literature using PubMed to identify studies that used the IFI27 biomarker to predict outcomes in COVID-19 patients. We used the search terms “IFI27”, “COVID-19, “gene expression” and “outcome prediction”. We did not identify any study that investigated the role of IFI27 biomarker in outcome prediction. Although ten studies were identified using the general terms of “gene expression” and “COVID-19”, IFI27 was only mentioned in passing as one of the identified genes. All these studies addressed the broader question of the host response to COVID-19; none focused solely on using IFI27 to improve the risk stratification of infected patients in a pandemic.
Added value of this study Here, we present the findings of a multi-cohort study of the IFI27 biomarker in COVID-19 patients. Our findings show that the host response, as reflected by blood IFI27 gene expression, accurately predicts COVID-19 disease progression (positive and negative predictive values; 0.83 and 0.95, respectively), outperforming age, comorbidity, C-reactive protein and all other known risk factors. The strong association of IFI27 with disease severity occurs not only in SARS-CoV-2 infection, but also in other respiratory viruses with pandemic potential, such as the influenza virus. These findings suggest that host response biomarkers, such as IFI27, could help identify high-risk COVID-19 patients - those who are more likely to develop infection complications - and therefore may help improve patient triage in a pandemic.
Implications of all the available evidence This is the first systemic study of the clinical role of IFI27 in the current COVID-19 pandemic and its possible future application in other respiratory virus pandemics. The findings not only could help improve the current management of COVID-19 patients but may also improve future pandemic preparedness.
Competing Interest Statement
FSFG is a consultant for Biotheus Inc. KRS is a consultant for Sanofi, Roche and NovoNordisk. The opinions and data presented in this manuscript are of the authors and are independent of these relationships. Other authors declare no competing interests.
Funding Statement
This research was funded by Centre of Research Excellence in Emerging Infectious Diseases (CREID; MS, BT), grants and fellowships from the National Health and Medical Research Council of Australia (1157741 AK; 1135898 GTB, 1140406 FSFG), Priority driven Collaborative Cancer Research Scheme, funded by Cure Cancer Australia with the assistance of Cancer Australia and the Can Too Foundation (1182179 AK; 1158085 FSFG), University of Queensland (GTB, FSFG, AK), Walter and Eliza Hall Institute of Medical Research (CT, MJD). MJD is supported by the Betty Smyth Centenary Fellowship in Bioinformatics. TRM is supported by an UQ PhD scholarship. FSFG is funded by the Australian and New Zealand Sarcoma Association Sarcoma Research Grant, and a US Department of Defence Breast Cancer Research Program breakthrough award level 1 (BC200025). Funding: CS is supported by the Lion Medical Research Foundation (2015001964), National Health and Medical Research Council (NHMRC 1195451). ENL is supported by Agencia Nacional de Investigacion y Desarrollo (COVID1005-ANID).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Cohort 1. Autopsy and biopsy materials were obtained from the Pontificia Universidade Catolica do Parana PUCPR the National Commission for Research Ethics (CONEP) under ethics committee approval reference number 2020001792/30188020.7.1001.0020 and approval reference number 2020001934/30822820.8.000.0020. The study was also approved under University of Queensland Human Research Ethics Committee (HREC) ratification. Cohort 2 & 4. This study was approved by the Human Research Ethics Committees of the University of Concepcion (Chile) (CEBB 676 2020) and ratified by the University of Queensland (2021/HE000319). All methods were performed in accordance with institutional guidelines and regulations. Written consent was obtained from all study participants. Cohort 3. The COVID19 samples in form of the nasopharyngeal swabs were procured from the TSB BioBank, which is part of the Translational Science BioCore (TSB) affiliated with the UW Carbone Cancer Center (UWCCC), University of Wisconsin Madison School of Medicine and Public Health, Madison, Wisconsin, USA. Informed consent was obtained from all subjects and the experiments conformed to the principles set out in the WMA Declaration of Helsinki and the Department of Health and Human Services Belmont Report. Cohort 5. This study has been approved by Human Research Ethics Committee of the Pontifocia Universidade Catolica do Parana (PUCPR) (Number CAAE 30833820.8.0000.0020) and by Comissao Nacional de Etica em Pesquisa (CONEP). All methods were performed in accordance with institutional guidelines and regulations. Written consent was obtained from all study participants. Cohort 6. This study was approved by the Mazandaran University of Medical Sciences (approval number IR.MAZUMS.REC 1399.856). All methods were performed in accordance with institutional guidelines and regulations. Written consent was obtained from all study participants. Cohort 7. Singaporean cohort: The study was approved by the National Healthcare Group Domain Specific Review Board (DSRB 2014/00614). Written informed consent was obtained from all study participants. Australia cohort: This study has been approved by Research Governance at the Westmead Institute for Medical Research, the Human Research Ethics Committee at Western Sydney Local Health District (HREC Reference 2020/ETH00886 (6439) and at Nepean Blue Mountain Local Health District (HREC Reference: 2019/ETH01485). Informed consent was obtained from all study participants. Cohort 8-10. The study has been approved by the Human Research Ethics Committee of Nepean and Blue Mountain Local Health District (HREC Reference 11/26 HREC/11/Nepean/46), Australia.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵* co-senior authors
Data Availability
All data produced in the present study are available upon reasonable request to the authors
